We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genome Mapping Reveals Genes that Contribute to Hypertension

By LabMedica International staff writers
Posted on 18 May 2009
Cardiovascular disease researchers used advanced gene mapping techniques to search for genes directly linked to blood pressure regulation.

High blood pressure (hypertension) is a syndrome that contributes to the risk of stroke, heart attack, and kidney failure, among other conditions. More...
Approximately 30% or more of adults suffer from high blood pressure, and experts suggest that it contributes to millions of deaths worldwide each year. While factors in the environment such as diet, physical activity, and stress affect blood pressure, there is also an important genetic influence that may contribute to the likelihood of an individual developing hypertension.

To study the genetic basis for high blood pressure investigators at Johns Hopkins University (Baltimore, MD, USA) mapped the genomes of nearly 30,000 people of European descent who were participants in the [U.S.] National Institutes of Health's ARIC (Atherosclerosis Risk in Communities) project. The subjects had average systolic blood pressures ranging from 118 mmHg to 143 mmHg and average diastolic blood pressures ranging from 72 mmHg to 83 mmHg.

Results published in the May 10, 2009, online edition of the journal Nature Genetics revealed that high blood pressure was linked to a mutation in the ATP2B1 gene, which codes for a calcium pump protein. A mutation in the SH2B3 gene, which codes for a protein involved in the immune response, was also found in individuals with increased blood pressure. In some of these individuals there were also mutations in genes involved in cell growth as well as genes necessary for correct heart development.

"Strikingly, none of the genes we identified as having common variation are part of the system we know about that regulates blood pressure – the genes identified are not the ones targeted by current prescription drugs to control hypertension,” said contributing author Dr. Aravinda Chakravarti, professor of genetic medicine at Johns Hopkins University. "If we can increase the number of genes implicated in blood pressure maintenance from the current 12 to the expected 50 in the next year, our understanding of the biology will change completely.”

"Hypertension is difficult to study; it is a trait, not a disease per se unless left untreated, and many things contribute to it,” said Dr. Chakravarti. "These findings identify more pathways important for blood pressure maintenance and may lead to improvements in hypertension therapy and the formation of early detection systems.”

Related Links:
Johns Hopkins University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.